Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A long term safety study to evaluate the Trabodenoson monotherapy in patients with ocular hypertension or open angle glaucoma

Next Previous
Trial Profile

A long term safety study to evaluate the Trabodenoson monotherapy in patients with ocular hypertension or open angle glaucoma

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 30 May 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabodenoson (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Inotek Pharmaceuticals

Most Recent Events

  • 31 Mar 2015 Inotek Pharmaceuticals expects to begin this trial in early 2017.If the primary objectives of phase III program are met, then Inotek Pharmaceuticals will submit a NDA to the US FDA for marketing approval of Trabodenoson for the treatment of glaucoma in the USA and plans to submit a MAA in Europe subsequently, according to the company SEC filing report 10-K 2014.
  • 31 Mar 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top